NOVARTIS SEEKS EU APPROVAL FOR GLIVEC APPLICATION

Swiss-based drug firm Novartis (NOVN.VX: Quote, Profile, Research) is seeking European approval to market its leukaemia treatment Glivec, the company said on Tuesday. Novartis hopes to market Glivec, or Gleevec, as a treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, either alone or in combination with chemotherapy.

Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=governmentFilingsNews&storyID=URI:urn:newsml:reuters.com:20051213:MTFH20431_2005-12-13_07-13-26_L13501514:1)